Merck And J&J Settle Remicade Dispute By Redrawing The Map
This article was originally published in The Pink Sheet Daily
Rather than let an arbitration panel decide the fate of two anti-TNF drugs, Merck surrenders many territories but holds onto Europe.
You may also be interested in...
J&J received approval to market a second TNF inhibitor to treat the bowel disorder. The authorization comes as Simponi’s increasing sales point toward blockbuster status.
Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.
FDA is asking for an additional round of label changes for the tumor necrosis factor inhibitor class, as a consequence of mounting evidence of cases of a rare and usually fatal type of lymphoma in patients taking the drugs.